» Articles » PMID: 24994678

HER2 Mediated De Novo Production of TGFβ Leads to SNAIL Driven Epithelial-to-mesenchymal Transition and Metastasis of Breast Cancer

Overview
Journal Mol Oncol
Date 2014 Jul 5
PMID 24994678
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

HER2 is an important determinant of poor prognosis in breast cancer patients. Studies indicate that HER2 positive tumors are mostly resistant to therapy and have high metastatic potential however, the underlying mechanisms remain unknown. In this study, MDA-MB-231 and MCF-7 breast cancer cells with their HER2 overexpressing syngeneic variants were used to delineate the role of HER2 in EMT and metastasis. Our results demonstrated that HER2 overexpression increased the invasive potential of cells. Our results also showed that HER2 overexpression lead to the production of TGFβ resulting in the activation of TGFβ/SMAD signaling. Furthermore, activation of SNAIL, SLUG and ZEB-1, the transcriptional repressors of E-cadherin and increased mesenchymal characteristics were observed in high HER2 cells. Interestingly, EMT by HER2 was mediated through TGFβ. Intravenous injection of high HER2 MDA-MB-231 (HH) cells in athymic nude mice showed early and substantial metastasis as compared to the parent cells establishing the direct role of HER2 in metastasis. Our results showed that inhibition of HER2 mediated EMT by cucurbitacin B a triterpenoid, resulted in the suppression of brain metastasis of breast cancer cells. Taken together, our results identify a novel mechanism of HER2 in promoting breast cancer metastasis through de novo synthesis of TGFβ leading to EMT, an initial and essential step of metastasis.

Citing Articles

Association Between Human Epidermal Growth Factor Receptor 2-Low Status and Time to Development of Brain Metastases Among Patients With Breast Cancer: A Retrospective Cohort Study.

Fan K, Chehade R, Fernandes I, Moravan V, Sahgal A, Warner E JCO Precis Oncol. 2025; 9:e2400641.

PMID: 40048670 PMC: 11895828. DOI: 10.1200/PO-24-00641.


Comprehensive molecular interaction map of TGFβ induced epithelial to mesenchymal transition in breast cancer.

Gottumukkala S, Ganesan T, Palanisamy A NPJ Syst Biol Appl. 2024; 10(1):53.

PMID: 38760412 PMC: 11101644. DOI: 10.1038/s41540-024-00378-w.


Biology of breast cancer brain metastases and novel therapies targeting the blood brain barrier: an updated review.

Zhao H, Wang L, Ji X, Zhang L, Li C Med Oncol. 2023; 40(6):181.

PMID: 37202575 DOI: 10.1007/s12032-023-02047-0.


The Journey of Cancer Cells to the Brain: Challenges and Opportunities.

Lazarczyk M, Mickael M, Skiba D, Kurzejamska E, Lawinski M, Horbanczuk J Int J Mol Sci. 2023; 24(4).

PMID: 36835266 PMC: 9967224. DOI: 10.3390/ijms24043854.


The super-enhancer repertoire in porcine liver.

Zhang Y, Zhang J, Wang C, Dai H, Du X, Li Q J Anim Sci. 2023; 101.

PMID: 36800318 PMC: 10024791. DOI: 10.1093/jas/skad056.


References
1.
Boreddy S, Sahu R, Srivastava S . Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and invasion by inhibiting HIF-α/VEGF/Rho-GTPases: pivotal role of STAT-3. PLoS One. 2011; 6(10):e25799. PMC: 3189946. DOI: 10.1371/journal.pone.0025799. View

2.
Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

3.
Taylor M, Parvani J, Schiemann W . The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia. 2010; 15(2):169-90. PMC: 3721368. DOI: 10.1007/s10911-010-9181-1. View

4.
Arend R, Londono-Joshi A, Straughn Jr J, Buchsbaum D . The Wnt/β-catenin pathway in ovarian cancer: a review. Gynecol Oncol. 2013; 131(3):772-9. DOI: 10.1016/j.ygyno.2013.09.034. View

5.
Gupta P, Srivastava S . Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models. BMC Med. 2012; 10:80. PMC: 3412708. DOI: 10.1186/1741-7015-10-80. View